Together, we demonstrated that MYC overexpression modified the cellular response to trametinib by enhancing the DNA damage response, as evidenced by the increased γH2A.X levels, while also partially mitigating transcriptional inhibition in HNSCC cells. This evidence concerns the gene PSMB5 and head and neck squamous cell carcinoma.